Skip to main content
. Author manuscript; available in PMC: 2021 Aug 18.
Published in final edited form as: Clin Cancer Res. 2020 Oct 2;26(24):6581–6588. doi: 10.1158/1078-0432.CCR-20-2283

Figure 2: OS by first-line treatment:

Figure 2:

Median OS (95% CI) in years in patients with MYC abnormality (blue curve) and without MYC abnormality (red curve) a) overall and among those who received b) PI-based, c) IMiD-based and d) PI+IMiD-based first line treatment. Abbreviations: Abn: abnormality, IMiD: immunomodulatory drug, NR: not reached, OS: overall survival, PI: proteasome inhibitor.